AstraZeneca LP v. Watson Laboratories Inc.
1:16-cv-00338
Overview
Parties
Defendant
Watson Laboratories Inc. Operating Company
Represented By
1 Attorneys ListedPotter Anderson & Corroon, LLP
1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951
AstraZeneca AB NPE (Individual / Inventor)
Represented By
3 Attorneys ListedMcCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
AstraZeneca LP NPE (Individual / Inventor)
Represented By
3 Attorneys ListedMcCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
Plaintiff
AstraZeneca Pharmaceuticals, LP NPE (Individual / Inventor)
Represented By
3 Attorneys ListedMcCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
AstraZeneca UK Limited NPE (University / Research)
Represented By
3 Attorneys ListedMcCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° RadarMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
AstraZeneca LP v. Amneal Pharmaceuticals LLC
AstraZeneca LP v. Prinston Pharmaceutical Inc.
AstraZeneca LP v. InvaGen Pharmaceuticals Inc.
AstraZeneca LP v. Mylan Pharmaceuticals Inc.
Patents Involved
There are 3 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US6525060
Triazolo(4,5-d)pyrimidine compounds
|
Filed: 1999-12-02
Issued: 2003-02-25
|
Expired (Term Ended)
Expires: 2019-12-02
|
|
|
US7250419
Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition
|
Filed: 2005-09-21
Issued: 2007-07-31
|
Expired (Term Ended)
Expires: 2025-09-21
|
|
|
US7265124
Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound
|
Filed: 2005-10-03
Issued: 2007-09-04
|
Expired (Term Ended)
Expires: 2021-07-09
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.
Standard Statutory Term — No obviousness-type double patenting truncation noted.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).